These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 33136674)
1. Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade. Sun MM; Seleme N; Chen JJ; Zekeridou A; Sechi E; Walsh RD; Beebe JD; Sabbagh O; Mejico LJ; Gratton S; Skidd PM; Bellows DA; Falardeau J; Fraser CL; Cappelen-Smith C; Haines SR; Hassanzadeh B; Seay MD; Subramanian PS; Williams Z; Gordon LK J Neuroophthalmol; 2021 Dec; 41(4):519-530. PubMed ID: 33136674 [TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
3. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553 [TBL] [Abstract][Full Text] [Related]
4. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Sun MM; Levinson RD; Filipowicz A; Anesi S; Kaplan HJ; Wang W; Goldstein DA; Gangaputra S; Swan RT; Sen HN; Gordon LK Ocul Immunol Inflamm; 2020; 28(2):217-227. PubMed ID: 30821569 [No Abstract] [Full Text] [Related]
5. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database. Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298 [TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. Chen YM J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088 [TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Song P; Zhang D; Cui X; Zhang L Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323 [TBL] [Abstract][Full Text] [Related]
12. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
13. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759 [TBL] [Abstract][Full Text] [Related]
14. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Dalvin LA; Shields CL; Orloff M; Sato T; Shields JA Retina; 2018 Jun; 38(6):1063-1078. PubMed ID: 29689030 [TBL] [Abstract][Full Text] [Related]
15. Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. Winges KM; Gordon LK Front Ophthalmol (Lausanne); 2022; 2():1044904. PubMed ID: 38983573 [TBL] [Abstract][Full Text] [Related]
16. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? Tanvetyanon T; Gray JE; Antonia SJ Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556 [TBL] [Abstract][Full Text] [Related]
17. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Ottaviano M; De Placido S; Ascierto PA Virchows Arch; 2019 Apr; 474(4):421-432. PubMed ID: 30747264 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Abolghasemi H; Ghaffari SH; Momeny M; Bashash D Eur J Pharmacol; 2021 Oct; 909():174404. PubMed ID: 34363829 [TBL] [Abstract][Full Text] [Related]
19. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531 [TBL] [Abstract][Full Text] [Related]
20. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Lee HT; Lee SH; Heo YS Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]